Search results for "Plasminogen"

showing 10 items of 142 documents

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

An unusual presentation of massive pulmonary embolism mimicking septal acute myocardial inferction treated with tenecteplase

2007

A 31-year-old man (175 cm, 82 kg) was referred to the emergency department 2 h after the sudden onset of acute dyspnea. Immediate ECG showed sinus tachycardia with ST elevations from V1 through V2 and a diagnosis of septal acute myocardial infarction was made. ECG on admission to the cardiology department showed the same results plus the S1-Q3-T3 pattern. Echocardiogram revealed a normally contracting left ventricle, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Thrombolytic therapy with tenecteplase 8000 IU and heparin 5000 IU was administered 5-10 min after hospitalisation and the patient was haemodynamic…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaSinus tachycardiaMyocardial InfarctionTenecteplaseDiagnosis DifferentialElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic Therapycardiovascular diseasesMyocardial infarctionInterventricular septumtenecteplasebusiness.industrymassive pulmonary embolismElectrocardiography in myocardial infarctionHematologymedicine.diseasePulmonary embolismmedicine.anatomical_structureVentricleTissue Plasminogen ActivatorCardiologySeptum of BrainRadiologyMyocardial infarction diagnosismedicine.symptomCardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR).

2013

Background Although physical exercise acutely increases the most widely used inflammatory biomarkers, there is no information on its effect on soluble urokinase plasminogen activating receptor (suPAR), a circulating biomarker increasingly used for the assessment of systemic inflammation. Methods suPAR was assessed with the quantitative suPARnostic Standard ELISA Assay (Virogates, Birkerod, Denmark) in 12 professional football players before and after a football match. The athletes were divided into two experimental groups. An oral dose of 300 mg of allopurinol was administered to one group of six participants four hours before a match; the other six participants received placebo. Results Se…

AdultMalemedicine.medical_specialtyacute exercise; allopurinol; suPARAllopurinolPhysical exerciseEnzyme-Linked Immunosorbent AssayallopurinolPlaceboSystemic inflammationacute exerciseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySuparnosticReceptors Urokinase Plasminogen ActivatorsuPARPlaceboschemistry.chemical_compoundInternal medicinemedicineHumansEnzyme InhibitorsXanthine oxidaseExerciseUrokinasebusiness.industrychemistrySuPARmedicine.symptombusinessmedicine.drug
researchProduct

The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.

1999

Abstract OBJECTIVES The impact of infection-associated antiphospholipid antibodies (APA) on endothelial cell activation, blood coagulation and fibrinolysis was evaluated in patients with infective endocarditis with and without major embolic events. BACKGROUND An embolic event is a common and severe complication of infective endocarditis. Despite the fact that APAs are known to be associated with infectious diseases, their pathogenic role in infective endocarditis has not been clearly defined. METHODS The relationship among the occurrence of major embolic events, echocardiographic vegetation size, endothelial cell activation, thrombin generation, fibrinolysis and APA was examined in 91 patie…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayGastroenterologyVon Willebrand factorRisk FactorsInternal medicinemental disordersFibrinolysisPlasminogen Activator Inhibitor 1medicineEndocarditisHumansRisk factorAgedRetrospective Studiesbiologybusiness.industryVascular diseaseFibrinolysisThrombinUltrasonography DopplerEndocarditis BacterialIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseasePrognosisHeart ValvesCerebral AngiographyInfective endocarditisImmunologybiology.proteinAntibodies AntiphospholipidFemaleCardiology and Cardiovascular MedicineComplicationbusinessTomography X-Ray Computedpsychological phenomena and processesProtein CBiomarkersEchocardiography Transesophagealmedicine.drugFollow-Up StudiesProtein CJournal of the American College of Cardiology
researchProduct

Pharmacological thrombolysis: one more weapon for free-flap salvage.

2005

Despite the high success rate of free-tissue transfer, thrombosis still complicates 5-30% of cases. Meticoulous technique, careful vessel selection, and pharmacological prophylaxis are not always enough to avoid thrombosis. Early diagnosis and reintervention provide the only way to salvage a thrombosed free flap, in case of either arterial or venous thrombosis. When kinking, torsion, or external compression of the pedicle are ruled out, and thrombectomy and redo of the anastomosis are unsuccessful, the last resort to save the flap is thrombolytic therapy. The authors present their experience with the salvage of two otherwise lost flaps by means of urokinase thrombolysis through direct intra…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFree flapAnastomosisTHERAPYSurgical FlapsMICROVASCULAR SURGERYFibrinolysismedicineMANAGEMENTHumansThrombolytic TherapyVeinUrokinaseAged 80 and overVenous Thrombosisbusiness.industrySTREPTOKINASE SALVAGEGraft SurvivalThrombolysisTHROMBECTOMYmedicine.diseaseThrombosisUrokinase-Type Plasminogen ActivatorSurgeryVenous thrombosismedicine.anatomical_structureSurgerybusinessmedicine.drugMicrosurgery
researchProduct

PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax

2019

Background and Objectives: Plasminogen activator inhibitor-1 (PAI-1) is a fibrinolytic system enzyme whose role in various fibrinolytic processes is currently unknown. In clinical manifestations of pleural liquids of diverse etiology, various levels of fibrinolytic activity can be observed&mdash

AdultMalemedicine.medical_specialtypleural effusion; malignant pleural effusion; plasminogen activator inhibitor-1Pleural effusionHydrothoraxGastroenterologyFibrinArticlechemistry.chemical_compoundpleural effusionInternal medicinemedicine.arteryPlasminogen Activator Inhibitor 1medicineMalignant pleural effusionHumansmalignant pleural effusionPleurisyAgedAged 80 and overlcsh:R5-920biologybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLatviaPleural Effusion MalignantchemistryEffusionPlasminogen activator inhibitor-1Pulmonary arterybiology.proteinHydrothoraxEtiologyplasminogen activator inhibitor-1Femalelcsh:Medicine (General)businessMedicina
researchProduct

Telemedicine for the acute management of stroke in Burgundy, France: an evaluation of effectiveness and safety

2016

Background In the context of the development of telemedicine in France to address low thrombolysis rates and limited stroke infrastructures, a star-shaped telestroke network was implemented in Burgundy (1.6 million inhabitants). We evaluated the safety and effectiveness of this network for thrombolysis in acute ischemic stroke patients. Methods One hundred and thirty-two consecutive patients who received intravenous thrombolysis during a telemedicine procedure (2012–2014) and 222 consecutive patients who were treated at the stroke center of Dijon University Hospital, France (2011–2012) were included. Main outcomes were the modified Rankin scale (mRS) score and case fatality at 3 months. Com…

AdultMalemedicine.medical_specialtythrombolysismedicine.medical_treatmentContext (language use)030204 cardiovascular system & hematologyLogistic regressionBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleNeoplasmsCase fatality ratemedicineHumansThrombolytic TherapyIntensive care medicineStrokeAgedAged 80 and overbusiness.industry[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieThrombolysisOdds ratioMiddle Agedmedicine.diseasestrokeConfidence interval3. Good healthTreatment OutcomeNeurologyTissue Plasminogen ActivatorEmergency medicineoutcomeFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)FrancePatient Safetyprognosistelemedicinebusiness030217 neurology & neurosurgery
researchProduct

In vitro Analysis of Synergistic Effects of Fibrinolytic Agents and Prostacyclin Analogues

1997

We investigated the in vitro thrombolytic effects of streptoki-nase, urokinase, alteplase and saruplase, alone or in combination, with the prostacyclin analogues, iloprost and taprostene. Human platelet-rich plasma was stimulated with collagen (1 μg/ml) to generate thrombi containing platelets and fibrin. Following treatment with fibrinolytic agents, lysis was allowed to proceed for 30 min and was then terminated with aprotinin (2,000 ClU/ml). To evaluate the combinatory effects of fibrinolytic agents and prostacyclin analogues, we used concentrations of fibrinolytic agents which reduced thrombi weight by less than 50%. Neither iloprost nor taprostene alone demonstrated any thrombolytic eff…

AdultMalemedicine.medical_treatmentProstacyclinPharmacologyFibrinolytic AgentsPhysiology (medical)Prostaglandins SyntheticFibrinolysismedicineHumansStreptokinaseIloprostUrokinaseChemistryFibrinolysisDrug SynergismHematologyDrug interactionEpoprostenolUrokinase-Type Plasminogen ActivatorIn vitroTissue Plasminogen Activatorcardiovascular systemFemaleSaruplaseFibrinolytic agentIloprostmedicine.drugPathophysiology of Haemostasis and Thrombosis
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct